Sorrento Therapeutics expands clinical development of resiniferatoxin
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
The Wall Street Journal: Sorrento Therapeutics sues billionaire Soon-Shiong over development of cancer drug
Sorrento Therapeutics Inc. alleges billionaire Patrick Soon-Shiong and .....»»
Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights
NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical bioph.....»»
Trillium Therapeutics Reports First Quarter 2018 Financial and Operating Results
Focusing TTI-621 clinical development on T.....»»
Anchiano Therapeutics Reports Third Quarter 2018 Financial and Operational Results
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced op.....»»
Protagonist Therapeutics to begin clinical development of PN-10943
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019
Geneva, Switzerland and Boston, MA –February 27, 2019 - ObsEva SA (NASDAQ:OBSV), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman.....»»
Sarepta doubles down on gene therapies after early Limb-Girdle data
As some biotechs struggle to meet the expectations placed upon gene therapies, Sarepta Therapeutics is investing further in the field, announcing a deal to purchase its development partner for $165 million after positive early clinical trial data. .....»»
Analysts Laud Sarepta"s "Increasingly Active" Gene Therapy Clinical Development
Sarepta Therapeutics Inc (NASDAQ: SRPT) reported fourth-quarter results Wednesday alongside positive results for its muscular dystrophy gene therapy candidate. .....»»
Mattson expands to Chicago with Hyde Park Group Food Innovation acquisition
Mattson, a food and beverage development company, has expanded to Chicago with its acquisition of the Hyde Park Group Food Innovation......»»
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data. read more.....»»
Sorrento Therapeutics announces first patient treated in Enbrel study
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Sorrento Therapeutics files to sell 616,655 shares of common stock for holders
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Sarepta"s stock is up 11% on positive data from clinical trial for Duchenne treatment
Shares of Sarepta Therapeutics Inc. gained 11.3% in trading on Tuesday after the co.....»»
Enlivex Therapeutics awarded second IIA grant to support Allocetra development
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Spero Therapeutics awarded up to $23M by NIAID for SPR206 development
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Foghorn Therapeutics doses first patient in clinical trial of FHD-286
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Yumanity Therapeutics to host virtual research and development day
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Harmony Biosciences announces clinical development update
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Larimar Therapeutics reports phase1 clinical trial data on CTI-1601 for
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»